News
Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome Doug Brunk September 21, 2023 0 ...
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...
Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback